Evaluation of the correlation between KRAS mutated allele frequency and pathologist tumorous nuclei percentage assessment in colorectal cancer suggests a role for zygosity status

J Clin Pathol. 2018 Aug;71(8):743-744. doi: 10.1136/jclinpath-2018-205085. Epub 2018 Apr 27.

Abstract

Evaluation of molecular tumour heterogeneity relies on the tumorous nuclei percentage (TNP) assessment by a pathologist, which has been criticised for being inaccurate and suffering from interobserver variability. Based on the 'Big Bang theory' which states that KRAS mutation in colorectal cancer is mostly homogeneous, we investigated this issue by performing a critical analysis of the correlation of the KRAS mutant allele fraction with the TNP in 99 colorectal tumour samples with a positive KRAS mutation status as determined by next-generation sequencing. Our results yield indirect evidence that the KRAS zygosity status influences the correlation between these parameters and we show that a well-trained pathologist is indeed capable of accurately assessing TNP. Our findings indicate that tumour zygosity, a feature which has largely been neglected until now, should be taken into account in future studies on (colorectal) molecular tumour heterogeneity.

Keywords: colorectal cancer; molecular pathology; quality assurance.

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Biopsy
  • Cell Nucleus / pathology*
  • Clinical Competence
  • Colorectal Neoplasms / genetics*
  • Colorectal Neoplasms / pathology*
  • DNA Mutational Analysis
  • Genetic Heterogeneity
  • Genetic Predisposition to Disease
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Mutation Rate
  • Mutation*
  • Pathologists*
  • Phenotype
  • Predictive Value of Tests
  • Proto-Oncogene Proteins p21(ras) / genetics*
  • Reproducibility of Results

Substances

  • Biomarkers, Tumor
  • KRAS protein, human
  • Proto-Oncogene Proteins p21(ras)